Detalles de la búsqueda
1.
Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet;
399(10336): 1708-1717, 2022 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35427481
2.
A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV.
Vaccines (Basel);
11(1)2022 Dec 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36679862
3.
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study.
EClinicalMedicine;
38: 100989, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34222848
4.
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Lancet Respir Med;
9(12): 1396-1406, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34655522
5.
Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
Vaccine;
37(13): 1827-1835, 2019 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30803843
6.
Clinical manifestations of a cluster of rotavirus infection in young infants hospitalized in neonatal care units.
J Microbiol Immunol Infect;
45(1): 15-21, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22154991
Resultados
1 -
6
de 6
1
Próxima >
>>